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Hyperuricemia has long been established as the major etiologic factor in gout. In recent years, a large body of evidence has
accumulated that suggests that hyperuricemia may play a role in the development and pathogenesis of a number of metabolic,
hemodynamic, and systemic pathologic diseases, including metabolic syndrome, hypertension, stroke, and atherosclerosis. A
number of epidemiologic studies have linked hyperuricemia with each of these disorders. In some studies, therapies that lower
uric acid may prevent or improve certain components of the metabolic syndrome. There is an association between uric acid and
the development of systemic lupus erythematosus; the connection between other rheumatic diseases such as rheumatoid arthritis
and osteoarthritis is less clear.Themechanism for the role of uric acid in disorders other than gout is not well established but recent
investigations point towards systemic inflammation induced by urate, as the major pathophysiological event common to systemic
diseases, including atherosclerosis.
1. Introduction
More than 150 years ago, Garrod observed that uric acid
is elevated in the blood of subjects with gout [1]. However,
ultimate proof that uric acid is a causative factor in gout
was not forthcoming for another 100 years when it was
demonstrated that intra-articular injection of sodium urate
produces acute arthritis [2]. Currently, it is well appreciated
that chronic hyperuricemia enhances deposition of uric acid
in tissues other than the joints, leading ultimately to tophi,
nephropathy, and kidney stones.
2. Hyperuricemia Is Not Limited to Gout
In recent years there has been a renewed interest in hyper-
uricemia and its association with a number of clinical disor-
ders other than gout, including hypertension, atherosclerosis,
cardiovascular disease, and chronic kidney disease. Indeed,
hyperuricemia is commonly part of the cluster of metabolic
and hemodynamic abnormalities including abdominal obe-
sity, glucose intolerance, insulin resistance, dyslipidemia, and
hypertension all often subsumed under the term “metabolic
syndrome” [3, 4]. Not only collectively, but also individu-
ally, hypertension, obesity, dyslipidemia, hyperglycemia, and
insulin resistance are positively correlated with serum levels
of uric acid [5–9].
3. Hyperuricemia and Metabolic Syndrome
and Its Components
The association between uric acid and metabolic syndrome
is robust throughout human development. Epidemiological
studies have demonstrated a close relationship between
serum uric acid (SUA) levels and the presence of metabolic
syndrome (and several of its components) among children
and adolescents as well as adults [10]. Some studies have
even noted the strong association between SUA and carotid
atherosclerosis among obese children [10, 11]. One study
analyzed the cross-sectional data of 1,370 US children and
adolescents aged 12–17 years from the National Health and
Nutrition Examination Survey (NHANES) 1999–2002 and
found a graded positive association between SUA and the
prevalence of metabolic syndrome or its components, inde-
pendent of classical risk factors. They found that of the five
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components of metabolic syndrome, SUA was significantly
associated with abdominal obesity, hypertriglyceridemia,
and hyperglycemia; there was only a borderline association
observed between SUA and high blood pressure.
Another compelling evidence suggests that hyperurice-
mia predicts the development of hypertension, obesity, and
type II diabetes mellitus [12, 13]. A prospective study from the
Framingham Heart Study original (𝑛 = 4883) and offspring
(𝑛 = 4292) cohorts showed that individuals with higher
serum uric acid, including younger adults, had higher future
risk of type 2 diabetes.
Several studies conducted since the early 1990s have
shown that increased serum uric acid precedes the develop-
ment of hypertension. Feig, in studies of hypertensive ado-
lescents, reported that an elevated uric acid over 5.5mg/dL
was observed in 90% of adolescents with newly diagnosed
primary disease [14]. Specifically, there exists a strong linear
correlation between serum uric acid and systolic blood
pressure.The same group conducted a double-blind, placebo-
controlled crossover study including 30 hypertensive adoles-
cents who were randomized to allopurinol or placebo for 4
weeks. While 86% of the intervention group became nor-
motensive following a decrease of uric acid below 5mg/dL,
this rate was only 3% in the control arm [15]. Another inter-
vention study conducted in asymptomatic hyperuricemic
patients documented benefits with allopurinol treatment in
terms of blood pressure and C-reactive protein (CRP). In a
landmark animal study by Mazzali et al. pharmacologically
induced mild-to-moderate hyperuricemia via oxonic acid
administration in rats resulted in the development of hyper-
tension. Remarkably when uric acid elevation was prevented
by treating with allopurinol or with a uricosuric agent,
the development of hypertension could be abrogated [16].
This study supports the hypothesis that there exists a direct
causative role for uric acid in the development of hyperten-
sion. Collectively, these data strongly suggest that uric acid
may have a pathogenic role in the development of metabolic
syndrome and associated cardiovascular disease, rather than
simply functioning as a surrogate marker for such disorders.
4. Hyperuricemia in Rheumatic Diseases
Other Than Gout
An association between hyperuricemia and rheumatic dis-
eases, besides gouty arthritis, has been observed in epidemi-
ologic studies. For example, in a study of 7374 adult women
(age >20 yrs) in the Third National Health and Nutrition
Examination Survey (NHANES), it was shown that women
self-reporting RA had significantly higher SUA levels com-
pared to women not self-reporting RA. In this study, pre-
dictors of SUA levels, besides self-reporting RA, were
race/ethnicity, being married, smoking, use of alcohol, high
body mass index, high C-reactive protein, elevated diastolic
or systolic blood pressure, and increased glomerular filtration
rate [17]. Furthermore, among patients with RA, one study
has shown that SUA levels are correlated with the risk of renal
dysfunction. SUA, independent of GFR, age, systolic blood
pressure, total cholesterol, triglycerides, and RA duration,
was determined to be a risk factor for kidney disease [18].
Similarly, Yang et al. demonstrated that SUA levels can be
used to predict the development of renal disease in patients
with SLE. The authors found that SUA is independently
associated with the development of lupus nephritis in SLE
patients [19].
There are also reports showing an association between
uric acid and osteoarthritis (OA). One study in OA patients
with hip replacement found that elevated SUA concentrations
were associatedwith the presence ofmultijoint handOA [20].
Another study has shown the occurrence of gout attacks in
joint sites that demonstrated radiographical OA such as big
toe, midfoot, knee, and distal finger joints. It is possible that
OA may facilitate the localized deposition of urate crystals
[21].
More recently, Denoble et al. assessed synovial fluid UA
concentration in patients with knee OA but with no clinical
signs for, or self-report of, gout and found that synovial fluid
UA concentrations correlated positively with radiographic
and scintigraphic measures of OA severity and synovial fluid
interleukins (IL-18 and IL-1𝛽) [22].
These findings suggest that synovial fluid UA is a risk
marker for OA severity. Furthermore, they show a correlation
between synovial fluidUA and IL-18 and IL-1𝛽, two cytokines
known to be produced by uric acid-activated inflamma-
somes. The association of synovial fluid IL-18 with OA pro-
gression also suggests the possibility that UA is a risk factor
promoting the pathological process of OA (possibly through
activation of the inflammasome).
5. Biochemistry and Biological Actions
of Uric Acid
Uric acid is the end product of purine metabolism in humans
and is generated by the action of the enzyme, xanthine
oxidase (XO), which catalyzes the last two steps of uric acid
conversion: hypoxanthine to xanthine and from xanthine to
uric acid.
For many years, uric acid was regarded as a metabolically
inert substance. However, there is ample evidence that uric
acid has multiple actions impacting cellular metabolism. For
example, uric acid can act as an endogenous antioxidant
and a powerful scavenger of single oxygen peroxyl (ROS)
and hydroxyl radicals (OH) [23]. Uric acid reacts with
peroxynitrite and stabilizes endothelial nitric oxide synthase
(eNOS) activity [24]. Its chemical limitations include the
fact that uric acid cannot scavenge superoxide and that the
presence of ascorbic acid in the plasma is required for its
antioxidant effect. Finally, uric acid paradoxically behaves
as a prooxidant and proinflammatory factor. A few points
should be emphasized to better understand this apparent
contradiction. First, uric acid functions differently inside
cells versus the extracellular milieu, where it is present in
soluble form [25]. Although it is a potent antioxidant in
extracellular fluid, uric acid exerts prooxidative effects once
inside the cell [26]. This effect is mediated by a NADPH
oxidase-dependent pathway. It has been demonstrated that
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plasma uric acid is a circulating marker of oxidant damage in
a variety of pathological conditions, including, among others,
ischemic liver injury, ischemic-reperfusion injury, hyperlipi-
demia, chronic heart failure, atherosclerosis, and diabetes
[27–31].Thus, inhibition of XOR by allopurinol or other XOR
inhibitors would be expected to reduce not only uric acid
production but also NADH, which results in a favorable shift
of NAD/NADH ratio.
6. Hyperuricemia and Atherosclerosis
Serum uric acid levels have an association with surrogate
markers of atherosclerosis in a number of studies. Surrogate
markers of atherosclerosis shown to have an association with
hyperuricemia include carotid intima-media thickness (C-
IMT) [11, 32–36], ankle brachial index [34], coronary artery
calcification [37], and brachial-ankle pulse wave velocity
(baPWV) [38]. In addition,many studies suggest an indepen-
dent effect of elevated serum uric acid on atherosclerosis as
measured by these surrogate markers after adjusting for the
influence of metabolic syndrome and other factors [11, 33, 35,
39]. In particular, there is evidence that uric acid has direct
effects on key processes involved in endothelial function and
vascular remodeling [40].
Xanthine oxidoreductase has two forms. In physiologic
conditions, it exists primarily as xanthine dehydrogenase,
which has greater affinity for oxidized nicotinamide adenine
reductase (NAD+) compared to oxygen. Under ischemic
conditions, xanthine dehydrogenase is converted to xanthine
oxidase. Xanthine oxidase uses oxygen as an electron accep-
tor instead of NAD+ resulting in the formation of superoxide
anion and hydrogen peroxide alongside uric acid. It is unclear
whether the resulting inflammation and arterial wall damage
associated with hyperuricemia are related to the free radicals
formed or to the uric acid itself [41].
As noted above, uric acid has both prooxidant and antiox-
idant activity. When acting an antioxidant, it chelates metals
and scavenges oxygen radicals [42]. As a prooxidant, uric
acid oxidizes lipids [43], reduces nitric oxide availability in
endothelial cells [44], and increases reactive oxygen species
[45]. Furthermore, as a prooxidant, high levels of serum
uric acid cause increased lipid oxidation [43]. The resultant
inflammation would be expected to disrupt reverse choles-
terol transport, a function that is important to reduce cardio-
vascular risk [46].
Oxidants also cause endothelial dysfunction by reacting
with and removing NO, thereby preventing vasodilation of
the endothelium. Decreased NO and increased reactive oxy-
gen species may promote a proinflammatory state that causes
endothelial dysfunction and contributes to atherosclerosis
and cardiovascular disease [47]. Finally, uric acid inhibits
endothelial cell proliferation and stimulates C-reactive pro-
tein production in endothelial cells [48].
At the level of vascular smooth muscle cells, uric
acid stimulates the production of monocyte chemoat-
tractant protein-1 (MCP-1), a key chemokine implicated
in atherosclerosis and chronic kidney disease. Increased
production of MCP-1 by uric acid appears to be mediated via
activation of mitogen-activated protein (MAP) kinase and
cyclooxygenase-2, leading to increased cell proliferation and
production of CRP and other inflammatory mediators [48].
Taken together, it is not surprising that several studies
show that elevated serum uric acid levels are predictive of
atherosclerosis or cardiovascular disease. For example, hyper-
tensive hyperuricemic patients have higher levels of BMI, C-
IMT, fasting plasma glucose, UA, hs-CRP, and proteinuria
as compared with hypertensive normouricemic subjects.
Hyperuricemia, per se, was found to be an independent
predictor for atherosclerosis in patients with hypertension
[33]. In another clinical study, serum uric acid was found
to be associated with subclinical atherosclerosis in men with
type II diabetes mellitus [34, 49]. Serum uric acid levels were
also higher in patients with rheumatoid arthritis (RA) and
cardiovascular disease than in those without cardiovascular
disease despite the fact that RA is not usually associated
with high serum uric acid levels [50]. Such findings do not
appear to be limited by gender. In womenwith systemic lupus
erythematosus, serum uric acid was found to be associated
with arterial stiffness and of potential use as an indicator of
subclinical atherosclerosis, although it was not independent
of age and homocysteine levels [51], nor is it likely the
situation that an absolute level of uric acid elevation is
necessary for injurious outcome. This was seen in a pop-
ulation of psoriatic arthritis patients with subclinical athero-
sclerosis [52]. Of note, most of the patients in this study
had serum uric acid levels that were in the normal reference
range even though there remained a link between subclinical
atherosclerosis and serum uric acid concentration [52]. This
may mean that the reference ranges for patients with chronic
inflammatory diseases may need to be adjusted. At the very
least, elevated levels of serum uric acid, even if within the
reference range, may need to be considered more carefully in
populations at higher risk for cardiovascular disease.
In summary, while it may be true that, under normal
physiologic conditions, uric acid functions as an antioxidant
and protects against atherosclerosis, it appears that, under
ischemic conditions, it becomes a prooxidant and increases
the risk of atherosclerosis [41].
Hence, it is as yet unclear what the role of lowering uric
acid may be in reducing cardiovascular disease risk. Further
study is needed to show if lowering serum uric acid will
also lower the incidence of atherosclerosis and cardiovascular
disease.
7. Urate as a Mediator of Inflammation
We now turn our attention to the involvement of uric acid in
systemic inflammation: a central pathophysiological feature
common to many forms of chronic noninfectious disorders
such as obesity, hypertension, chronic heart failure, and
cardiovascular disease, as well as generalized atherosclerosis.
Indeed, there are epidemiological studies showing a rela-
tionship between serum uric acid and markers of systemic
inflammation. In several population-based studies [53] in
4 ISRN Rheumatology
healthy men and women, serum uric acid is associated posi-
tively with CRP [54]. Similarly, serum uric acid is positively
associated not only with CRP, but also with IL-6 and TNF-
𝛼, as reported in a study of 957 elderly individuals in Italy
[55]. Moreover, serum uric acid predicted CRP increase
during follow-up assessment [30]. In another population-
based study conducted in Switzerland that included 6085
Caucasians aged 35 to 75 years, serum uric acid was found to
be positively associated with CRP, TNF-𝛼, and IL-6 (in both
men and women) [56]. In patients with chronic heart failure,
SUA is associated positively with TNF-𝛼 and IL-6. And in
patients withmetabolic syndrome, several components of the
syndrome, including serum uric acid levels, are strongly cor-
related with serum levels of CRP, IL-6, and fibrinogen, again,
consistent with high inflammatory activity [57]. Finally, there
is experimental evidence that suggests that uric acid can
directly stimulate the release of TNF-𝛼. Specifically, infusion
of soluble uric acid into mice produces a marked increase
in circulating TNF-𝛼 levels [58]. Studies by di Giovine et al.
have demonstrated that urate crystals stimulate production
of TNF-𝛼 from human blood monocytes and synovial cells
[59]. Along similar lines, cell culture experiments by Bordoni
et al. have highlighted the role of uric acid in inflammation
by demonstrating its role in signal transduction within
the apoptotic pathway and also confirming that uric acid
stimulates mononuclear cells to produce TNF-𝛼 [60].
Recently, Kono and coworkers, in a series of in vivo
studies, demonstrated that uric acid plays a key role in the
inflammatory response to necrotic cells in mice.These inves-
tigators found that dead cells not only release intracellular
stores of uric acid but also produce it in large amounts post-
mortem (as nucleic acids were degraded) [61]. Using a newly
developed transgenic (Tg) mouse that has reduced levels
of uric acid, they further showed that uric acid depletion
substantially reduces the cell death-induced inflammatory
response. Similar results have been obtained with pharma-
cological treatments that reduced uric acid levels by either
blocking its synthesis or hydrolyzing it in the extracellular
fluids. Additionally, uric acid depletion selectively inhibits the
inflammatory response to dying cells but not to microbial
molecules or sterile irritant particles. Taken together, these
data indicate that uric acid acts as an endogenous proinflam-
matorymolecule released from dying cells as a result of tissue
damage.
Recently, a critical role of intracellular inflammasomes
(such as NALP3) has been identified. Innate immune com-
plexes known to be responsible for triggering inflamma-
tion in response to danger-associated molecular patterns
(DAMPs) have been implicated in MSU crystal associated
inflammation [62, 63]. The inflammatory effect of MSU
crystals appears to bemediated to a large extent by theNLRP3
inflammasome that drives IL-1𝛽 and IL-18 production. IL-
1𝛽 is likely the main agent to trigger systemic inflamma-
tion, promoting extensive neutrophil infiltration and tissue
restructuring [64]. Further evidence for a role of UA in
inflammasome activation is the finding that inflammasome
activation by pure synthetic hemozoin is reduced by allop-
urinol [65].
8. Urate and Innate and Adaptive Immunity
Uric acid is a danger signal that alerts the immune system
to cell injury and triggers both innate and adaptive immune
responses. It has been shown that dying cells injected into
animals along with an antigen create a strong adjuvant effect
and significantly increase the immune response to the initial
antigen. Microcrystalline UA released from injured cells may
be the danger signal triggering this adjuvant effect through
the stimulation of CD8+ T cells [66].
Studies by Liu-Bryan et al. also implicate innate immune
cellular recognition of naked MSU crystals by specific Toll-
like receptors (TLRs) as a major factor in determining
the inflammatory potential of MSU crystal deposits [67].
Recently it was shown that UA crystals in the presence of
NF-𝜅B signaling were capable of stimulating dendritic cells to
promote the release of cytokines associated with Th17 polar-
ization indicating, a novel role for UA in driving proinflam-
matory Th17, suggesting that sterile inflammation modulates
adaptive immunity, in addition to influencing early innate
responses [68].
In summary, evidence has emerged that points towards a
new interpretation of the pathophysiological role of uric acid.
No longer can we view it simply as a phenomenon restricted
to gout, but rather as an active agent involved in systemic
inflammatory and innate immune responses. It is becoming
clear that uric acid is not only a marker of the metabolic
syndrome and associated cardiovascular risk factors, but also
an agent provocateur of systemic inflammation and the innate
immune response that contributes to the development and
pathogenesis of cardiovascular disease. Indeed, it may be a
key measure of blood vessel inflammation. This has implica-
tions not only for the metabolic syndrome (and accelerated
atherosclerosis) but likely also for autoimmune vascular
diseases such as vasculitis. Therefore, it is not surprising that
patients with SLE and metabolic syndrome have significantly
raised serum uric acid [69].
In short, an inflammatory microangiopathy may be seen
in patients with connective tissue disease and uric acid
may be an active participant in the process. It may be that
physiologic signal transduction mediated by reactive oxygen
species (ROS) along with the possibility of rapid XD to XO
conversion plays a role as a trigger for the microvascular
inflammatory response to clinical states of vascular injury
[70].
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